Replies to post #78803 on Biotech Values

[DewDiligence]

VRX re taribavirin PR:

This may be yet another case where the word encouraging in the PR header means exactly the opposite. I do not think anyone wants this drug. Nowhere in the PR does it say that there are plans to conduct or even design a phase-3 trial.

[DewDiligence]

VRX – This is one for conspiracy types: Today’s WSJ has an over-the-top glowing piece on the executive-compensation decision-making at VRX, and then the company announces at 8am ET that its drug for postherpetic neuralgia failed a phase-2 trial:

http://www.reuters.com/article/marketsNews/idINBNG28554720090824

The share price fell (only) 8.5%.